Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity medications.

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially benefiting millions of Americans struggling with obesity.